FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Equine Vet J / A systematic review and meta-analysis of the efficacy of pla...
Equine veterinary journal2024; 56(5); 858-869; doi: 10.1111/evj.14042

A systematic review and meta-analysis of the efficacy of platelet-rich plasma products for treatment of equine joint disease.

Abstract: Equine joint disease including septic arthritis (SA) and osteoarthritis (OA) is a critical cause of equine lameness. Platelet-rich plasma (PRP) is one of the most popular regenerative therapies to treat equine OA, even SA, but the evidence in support of the treatment is conflicting. Objective: The aim of the study was to systematically review the current evidence on PRP products used for SA and OA, as well as the efficacy of PRP products as treatment for OA on the basis of a meta-analysis of the available literature. Methods: Systematic review and meta-analysis. Methods: A systematic search of relevant databases (PubMed, Web of Science, Scopus) was performed to identify studies published from 2013 to 2023, in accordance with the PRISMA guidelines. Randomised controlled trials, non-randomised trials and controlled laboratory studies that used at least one type of PRP products were included. Dichotomous outcomes were presented using odds ratios (ORs) and 95% confidence intervals (95% CIs). Results: A total of 21 publications were identified in the systematic review and 5 of them in the meta-analysis. These publications involved various types of PRP products and reported different outcomes. Although most of the studies were associated with a high risk of bias, the overall estimated effect was consistent with a significant improvement in the PRP products treatment group compared with the control group (OR: 15.32; 95% CI: 3.00-78.15; p < 0.05). There was a significant improvement in clinical performance outcomes between the groups (OR: 36.64; 95% CI: 3.69-364.30; p < 0.05). Conclusions: PRP products as intra-articular treatment are likely efficacious for treatment of equine OA and have potential for treating SA. These conclusions might be affected by the limited number of randomised controlled studies and high variability of different types of PRP products. To better evaluate the efficacy of PRP, a widely recognised classification system and the utilisation of randomised, blinded, equivalency or non-inferiority trials are required.
© 2024 EVJ Ltd.
Get Full Text
Publication Date: 2024-01-07 PubMed ID: 38185481DOI: 10.1111/evj.14042Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Systematic Review
  • Journal Article
  • Meta-Analysis

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research explores the effectiveness of platelet-rich plasma (PRP) therapies in treating horse joint diseases like septic arthritis (SA) and osteoarthritis (OA), drawing from a plethora of studies and analysing their published results.

Overview of the Study

  • This study embarked on a rigorous and systematic investigation into previous research conducted on the use of PRP therapies in addressing equine joint diseases, specifically septic arthritis (SA) and osteoarthritis (OA).
  • The researchers’ objective was to assess the available evidence on the use and efficacy of PRP products for SA and OA.

Methodology

  • A thorough search through specific databases including PubMed, Web of Science, and Scopus was undertaken to identify studies done from 2013 to 2023.
  • The adopted approach for fishing out essential studies was in line with the PRISMA guidelines.
  • The investigation examined various studies, including randomised controlled trials, non-randomised trials, and controlled laboratory studies that used at least one type of PRP product.
  • Data obtained through these studies were carefully categorised and evaluated based on odds ratios (ORs) and 95% confidence intervals (95% CIs).

Results

  • A total of 21 publications relating to PRP use in equine joint diseases were identified and thoroughly reviewed, with 5 meeting the criteria for inclusion in the final meta-analysis.
  • The studies encompassed a variety of PRP products and reported diverse outcomes.
  • Despite the perceived high risk of bias in many of the studies, the cumulative effect hinted at a possible improvement in the treatment group that used PRP products when compared with the control group.
  • Specifically, the utilisation of PRP therapies showed significant improvement in horses’ clinical performance outcomes.

Conclusions

  • The researchers concluded that PRP products, when administered intra-articularly, are likely efficacious in the treatment of equine OA and could also have potential benefits for treating SA.
  • However, they cautioned that these conclusions could be influenced by the limited number of randomised controlled studies reviewed and the wide variability of different types of PRP products.
  • Therefore, they recommend adopting a universally accepted classification system and engaging in more randomised, blinded, equivalency or non-inferiority trials to better evaluate the efficacy of PRP.

Cite This Article

APA
Peng C, Yang L, Labens R, Gao Y, Zhu Y, Li J. (2024). A systematic review and meta-analysis of the efficacy of platelet-rich plasma products for treatment of equine joint disease. Equine Vet J, 56(5), 858-869. https://doi.org/10.1111/evj.14042

Publication

Equine veterinary journal
ISSN: 2042-3306
NlmUniqueID: 0173320
Country: United States
Language: English
Volume: 56
Issue: 5
Pages: 858-869

Researcher Affiliations

Peng, Cong
  • Equine Clinical Diagnostic Center, College of Veterinary Medicine, China Agricultural University, Beijing, China.
Yang, Luo
  • Equine Clinical Diagnostic Center, College of Veterinary Medicine, China Agricultural University, Beijing, China.
Labens, Raphael
  • School of Agricultural, Environmental and Veterinary Sciences, Charles Sturt University, Bathurst, New South Wales, Australia.
Gao, Yu
  • University of Veterinary Medicine Hannover, Hanover, Lower Saxony, Germany.
Zhu, Yiping
  • Equine Clinical Diagnostic Center, College of Veterinary Medicine, China Agricultural University, Beijing, China.
Li, Jing
  • Equine Clinical Diagnostic Center, College of Veterinary Medicine, China Agricultural University, Beijing, China.
  • China Agricultural University Veterinary Teaching Hospital, Beijing, China.

MeSH Terms

  • Horses
  • Animals
  • Platelet-Rich Plasma
  • Horse Diseases / therapy
  • Joint Diseases / veterinary
  • Joint Diseases / therapy
  • Osteoarthritis / veterinary
  • Osteoarthritis / therapy

Grant Funding

  • 1051-2221005 / Talent Fund of China Agricultural University Veterinary Teaching Hospital (Beijing Zhongnongda Veterinary Hospital Co., Ltd.)

References

This article includes 73 references
  1. Contino EK. Management and rehabilitation of joint disease in sport horses. Vet Clin North Am: Equine Pract 2018;34(2):345–358.
    doi: 10.1016/j.cveq.2018.04.007google scholar: lookup
  2. McIlwraith CW, Vachon A. Review of pathogenesis and treatment of degenerative joint disease. Equine Vet J 1988;20(s6):3–11.
    doi: 10.1111/j.2042-3306.1988.tb04641.xgoogle scholar: lookup
  3. Ireland JL, Clegg PD, McGowan CM, McKane SA, Chandler KJ, Pinchbeck GL. Disease prevalence in geriatric horses in the United Kingdom: veterinary clinical assessment of 200 cases. Equine Vet J 2012;44(1):101–106.
    doi: 10.1111/j.2042-3306.2010.00361.xgoogle scholar: lookup
  4. Revenaugh MS. Extracorporeal shock wave therapy for treatment of osteoarthritis in the horse: clinical applications. Vet Clin North Am: Equine Pract 2005;21(3):609–625, vi.
    doi: 10.1016/j.cveq.2005.09.001google scholar: lookup
  5. Baek SH, Kim SY. Pharmacologic treatment of osteoarthritis. J Korean Med Assoc 2013;56(12):1123–1131.
    doi: 10.5124/jkma.2013.56.12.1123google scholar: lookup
  6. Garbin LC, Lopez C, Carmona JU. A critical overview of the use of platelet‐rich plasma in equine medicine over the last decade. Front Vet Sci 2021;8:641818.
    doi: 10.3389/fvets.2021.641818google scholar: lookup
  7. Schneider RK, Bramlage LR, Moore RM, Mecklenburg LM, Kohn CW, Gabel AA. A retrospective study of 192 horses affected with septic arthritis/tenosynovitis. Equine Vet J 1992;24(6):436–442.
    doi: 10.1111/j.2042-3306.1992.tb02873.xgoogle scholar: lookup
  8. Gilbertie JM, Schnabel LV, Hickok NJ, Jacob ME, Conlon BP, Shapiro IM. Equine or porcine synovial fluid as a novel ex vivo model for the study of bacterial free‐floating biofilms that form in human joint infections. PLoS One 2019;14(8):e0221012.
    doi: 10.1371/journal.pone.0221012google scholar: lookup
  9. Pezzanite LM, Hendrickson DA, Dow S, Stoneback J, Chow L, Krause D. Intra‐articular administration of antibiotics in horses: justifications, risks, reconsideration of use and outcomes. Equine Vet J 2022;54(1):24–38.
    doi: 10.1111/evj.13502google scholar: lookup
  10. Egerbacher M, Edinger J, Tschulenk W. Effects of enrofloxacin and ciprofloxacin hydrochloride on canine and equine chondrocytes in culture. Am J Vet Res 2001;62(5):704–708.
    doi: 10.2460/ajvr.2001.62.704google scholar: lookup
  11. Pezzanite L, Chow L, Soontararak S, Phillips J, Goodrich L, Dow S. Amikacin induces rapid dose‐dependent apoptotic cell death in equine chondrocytes and synovial cells in vitro. Equine Vet J 2020;52(5):715–724.
    doi: 10.1111/evj.13243google scholar: lookup
  12. Pezzanite L, Chow L, Piquini G, Griffenhagen G, Ramirez D, Dow S. Use of in vitro assays to identify antibiotics that are cytotoxic to normal equine chondrocytes and synovial cells. Equine Vet J 2021;53(3):579–589.
    doi: 10.1111/evj.13314google scholar: lookup
  13. Herdan CL, Acke E, Dicken M, Archer RM, Forsyth SF, Gee EK. Multi‐drug‐resistant enterococcus spp. as a cause of non‐responsive septic synovitis in three horses. N Z Vet J 2012;60(5):297–304.
    doi: 10.1080/00480169.2011.651702google scholar: lookup
  14. Loncaric I, Künzel F, Licka T, Simhofer H, Spergser J, Rosengarten R. Identification and characterization of methicillin‐resistant Staphylococcus aureus (MRSA) from Austrian companion animals and horses. Vet Microbiol 2014;168(2–4):381–387.
    doi: 10.1016/j.vetmic.2013.11.022google scholar: lookup
  15. Maddox TW, Clegg PD, Williams NJ, Pinchbeck GL. Antimicrobial resistance in bacteria from horses: epidemiology of antimicrobial resistance. Equine Vet J 2015;47(6):756–765.
    doi: 10.1111/evj.12471google scholar: lookup
  16. Van den Eede A, Hermans K, Van den Abeele A, Floré K, Dewulf J, Vanderhaeghen W. Methicillin‐resistant Staphylococcus aureus (MRSA) on the skin of long‐term hospitalised horses. Vet J 2012;193(2):408–411.
    doi: 10.1016/j.tvjl.2011.12.004google scholar: lookup
  17. Wessely‐Szponder J, Zdziennicka J, Junkuszew A, Latalski M, Świeca M, Szponder T. Prospects and applications of natural blood‐derived products in regenerative medicine. Int J Mol Sci 2021;23(1):472.
    doi: 10.3390/ijms23010472google scholar: lookup
  18. Tang YQ, Yeaman MR, Selsted ME. Antimicrobial peptides from human platelets. Infect Immun 2002;70(12):6524–6533.
    doi: 10.1128/iai.70.12.6524-6533.2002google scholar: lookup
  19. Woodell‐May JE, Sommerfeld SD. Role of inflammation and the immune system in the progression of osteoarthritis. J Orthop Res 2020;38(2):253–257.
    doi: 10.1002/jor.24457google scholar: lookup
  20. Szponder T, Wessely‐Szponder J, Smolira A. Evaluation of platelet‐rich plasma and neutrophil antimicrobial extract as two autologous blood‐derived agents. Tissue Eng Regen Med 2017;14(3):287–296.
    doi: 10.1007/s13770-017-0035-4google scholar: lookup
  21. Alabdullatif M, Atreya CD, Ramirez‐Arcos S. Antimicrobial peptides: an effective approach to prevent bacterial biofilm formation in platelet concentrates. Transfusion 2018;58(8):2013–2021.
    doi: 10.1111/trf.14646google scholar: lookup
  22. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet‐rich plasma (P‐PRP) to leucocyte‐ and platelet‐rich fibrin (L‐PRF). Trends Biotechnol 2009;27(3):158–167.
    doi: 10.1016/j.tibtech.2008.11.009google scholar: lookup
  23. Mishra A, Harmon K, Woodall J, Vieira A. Sports medicine applications of platelet rich plasma. Curr Pharm Biotechnol 2012;13(7):1185–1195.
    doi: 10.2174/138920112800624283google scholar: lookup
  24. DeLong JM, Russell RP, Mazzocca AD. Platelet‐rich plasma: the paw classification system. Art Ther 2012;28(7):998–1009.
    doi: 10.1016/j.arthro.2012.04.148google scholar: lookup
  25. Mautner K, Malanga GA, Smith J, Shiple B, Ibrahim V, Sampson S. A call for a standard classification system for future biologic research: the rationale for new PRP nomenclature. PM&R 2015;7(4 Suppl):S53–S59.
    doi: 10.1016/j.pmrj.2015.02.005google scholar: lookup
  26. Magalon J, Chateau AL, Bertrand B, Louis ML, Silvestre A, Giraudo L. DEPA classification: a proposal for standardising PRP use and a retrospective application of available devices. BMJ Open Sport Exerc Med 2016;2(1):e000060.
    doi: 10.1136/bmjsem-2015-000060google scholar: lookup
  27. Garbin LC, Olver CS. Platelet‐rich products and their application to osteoarthritis. J Equine Vet 2020;86:102820.
    doi: 10.1016/j.jevs.2019.102820google scholar: lookup
  28. Zamani M, Yaghoubi Y, Movassaghpour A, Shakouri K, Mehdizadeh A, Pishgahi A. Novel therapeutic approaches in utilizing platelet lysate in regenerative medicine: are we ready for clinical use?. J Cell Physiol 2019;234(10):17172–17186.
    doi: 10.1002/jcp.28496google scholar: lookup
  29. Piccin A, Di Pierro AM, Canzian L, Primerano M, Corvetta D, Negri G. Platelet gel: a new therapeutic tool with great potential. Blood Transfus 2017;15(4):333–340.
    doi: 10.2450/2016.0038-16google scholar: lookup
  30. Andia I, Perez‐Valle A, Del Amo C, Maffulli N. Freeze‐drying of platelet‐rich plasma: the quest for standardization. Int J Mol Sci 2020;21(18):6904.
    doi: 10.3390/ijms21186904google scholar: lookup
  31. Zanotto GM, Frisbie DD. Current joint therapy usage in equine practice: changes in the last 10 years. Equine Vet J 2022;54(4):750–756.
    doi: 10.1111/evj.13489google scholar: lookup
  32. Boswell SG, Cole BJ, Sundman EA, Karas V, Fortier LA. Platelet‐rich plasma: a milieu of bioactive factors. Art Ther 2012;28(3):429–439.
    doi: 10.1016/j.arthro.2011.10.018google scholar: lookup
  33. Brossi PM, Moreira JJ, Machado TS, Baccarin RY. Platelet‐rich plasma in orthopedic therapy: a comparative systematic review of clinical and experimental data in equine and human musculoskeletal lesions. BMC Vet Res 2015;11:98.
    doi: 10.1186/s12917-015-0403-zgoogle scholar: lookup
  34. Laudy AB, Bakker EW, Rekers M, Moen MH. Efficacy of platelet‐rich plasma injections in osteoarthritis of the knee: a systematic review and meta‐analysis. Br J Sports Med 2015;49(10):657–672.
    doi: 10.1136/bjsports-2014-094036google scholar: lookup
  35. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP. The Prisma statement for reporting systematic reviews and meta‐analyses of studies that evaluate healthcare interventions: explanation and elaboration. Br Med J 2009;339:b2700.
    doi: 10.1136/bmj.b2700google scholar: lookup
  36. Wasai S, Sato M, Maehara M, Toyoda E, Uchiyama R, Takahashi T. Characteristics of autologous protein solution and leucocyte‐poor platelet‐rich plasma for the treatment of osteoarthritis of the knee. Sci Rep 2020;10(1):10572.
    doi: 10.1038/s41598-020-67099-ygoogle scholar: lookup
  37. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ. Cochrane handbook for systematic reviews of interventions. Hoboken, NJ: Wiley; 2019.
  38. Friedrich JO, Adhikari NK, Beyene J. Inclusion of zero total event trials in meta‐analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol 2007;7:5.
    doi: 10.1186/1471-2288-7-5google scholar: lookup
  39. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data. Stat Med 2004;23(9):1351–1375.
    doi: 10.1002/sim.1761google scholar: lookup
  40. Gordon J, Álvarez‐Narváez S, Peroni JF. Antimicrobial effects of equine platelet lysate. Front Vet Sci 2021;8:703414.
    doi: 10.3389/fvets.2021.703414google scholar: lookup
  41. Gilbertie JM, Schaer TP, Schubert AG, Jacob ME, Menegatti S, Ashton Lavoie R. Platelet‐rich plasma lysate displays antibiofilm properties and restores antimicrobial activity against synovial fluid biofilms in vitro. J Orthop Res 2020;38(6):1365–1374.
    doi: 10.1002/jor.24584google scholar: lookup
  42. Gilbertie JM, Long JM, Schubert AG, Berglund AK, Schaer TP, Schnabel LV. Pooled platelet‐rich plasma lysate therapy increases synoviocyte proliferation and hyaluronic acid production while protecting chondrocytes from synoviocyte‐derived inflammatory mediators. Front Vet Sci 2018;5:150.
    doi: 10.3389/fvets.2018.00150google scholar: lookup
  43. Palma HE, Gallio M, Da Silva GB, Cantarelli C, Bertolin K, Wolkmer P. Comparison of the effects of triamcinolone acetonide or platelet‐rich plasma on expression of extracellular matrix‐related genes in equine healthy chondrocytes in vitro. Cienc Rural 2019;49(7):1–7.
    doi: 10.1590/0103-8478cr20180262google scholar: lookup
  44. De Angelis E, Grolli S, Saleri R, Conti V, Andrani M, Berardi M. Platelet lysate reduces the chondrocyte dedifferentiation during in vitro expansion: implications for cartilage tissue engineering. Res Vet Sci 2020;133:98–105.
    doi: 10.1016/j.rvsc.2020.08.017google scholar: lookup
  45. Ríos DL, López C, Carmona JU. Evaluation of the anti‐inflammatory effects of two platelet‐rich gel supernatants in an in vitro system of cartilage inflammation. Cytokine 2015;76(2):505–513.
    doi: 10.1016/j.cyto.2015.07.008google scholar: lookup
  46. Garbin LC, McIlwraith CW, Frisbie DD. Evaluation of allogeneic freeze‐dried platelet lysate in cartilage exposed to interleukin 1‐Β in vitro. BMC Vet Res 2019;15(1):386.
    doi: 10.1186/s12917-019-2118-zgoogle scholar: lookup
  47. Carmona JU, Rios DL, Lopez C, Alvarez ME, Perez JE, Bohorquez ME. In vitro effects of platelet‐rich gel supernatants on histology and chondrocyte apoptosis scores, hyaluronan release and gene expression of equine cartilage explants challenged with lipopolysaccharide. BMC Vet Res 2016;12(1):135.
  48. Velloso Alvarez A, Boone LH, Pondugula SR, Caldwell F, Wooldridge AA. Effects of autologous conditioned serum, autologous protein solution, and triamcinolone on inflammatory and catabolic gene expression in equine cartilage and synovial explants treated with il‐1β in co‐culture. Front Vet Sci 2020;7:323.
    doi: 10.3389/fvets.2020.00323google scholar: lookup
  49. Textor JA, Willits NH, Tablin F. Synovial fluid growth factor and cytokine concentrations after intra‐articular injection of a platelet‐rich product in horses. Vet J 2013;198(1):217–223.
    doi: 10.1016/j.tvjl.2013.07.020google scholar: lookup
  50. Bertone AL, Ishihara A, Zekas LJ, Wellman ML, Lewis KB, Schwarze RA. Evaluation of a single intra‐articular injection of autologous protein solution for treatment of osteoarthritis in horses. Am J Vet Res 2014;75(2):141–151.
    doi: 10.2460/ajvr.75.2.141google scholar: lookup
  51. Broeckx S, Zimmerman M, Crocetti S, Suls M, Marien T, Ferguson SJ. Regenerative therapies for equine degenerative joint disease: a preliminary study. PLoS One 2014;9(1):e85917.
    doi: 10.1371/journal.pone.0085917google scholar: lookup
  52. Pichereau F, Décory M, Cuevas Ramos G. Autologous platelet concentrate as a treatment for horses with refractory fetlock osteoarthritis. J Equine Vet 2014;34(4):489–493.
    doi: 10.1016/j.jevs.2013.10.004google scholar: lookup
  53. Moraes AP, Moreira JJ, Brossi PM, Machado TS, Michelacci YM, Baccarin RY. Short‐ and long‐term effects of platelet‐rich plasma upon healthy equine joints: clinical and laboratory aspects. Can Vet J 2015;56(8):831–838.
  54. Bembo F, Eraud J, Philandrianos C, Bertrand B, Silvestre A, Veran J. Combined use of platelet rich plasma & micro‐fat in sport and race horses with degenerative joint disease: preliminary clinical study in eight horses. Muscles Ligaments Tendons Journal 2016;6(2):198–204.
    doi: 10.11138/mltj/2016.6.2.198google scholar: lookup
  55. Mirza MH, Bommala P, Richbourg HA, Rademacher N, Kearney MT, Lopez MJ. Gait changes vary among horses with naturally occurring osteoarthritis following intra‐articular administration of autologous platelet‐rich plasma. Front Vet Sci 2016;3:29.
    doi: 10.3389/fvets.2016.00029google scholar: lookup
  56. Tyrnenopoulou P, Diakakis N, Karayannopoulou M, Savvas I, Koliakos G. Evaluation of intra‐articular injection of autologous platelet lysate (pl) in horses with osteoarthritis of the distal interphalangeal joint. Vet Q 2016;36(2):56–62.
    doi: 10.1080/01652176.2016.1141257google scholar: lookup
  57. Smit Y, Marais HJ, Thompson PN, Mahne AT, Goddard A. Clinical findings, synovial fluid cytology and growth factor concentrations after intra‐articular use of a platelet‐rich product in horses with osteoarthritis. J S Afr Vet Assoc 2019;90:e1–e9.
  58. Perrone G, Lastra Y, Gonzalez C, Caggiano N, Gimenez R, Pareja R. Treatment with platelet lysate inhibits proteases of synovial fluid in equines with osteoarthritis. J Equine Vet 2020;88:102952.
  59. Garbin LC, Contino EK, Olver CS, Frisbie DD. A safety evaluation of allogeneic freeze‐dried platelet‐rich plasma or conditioned serum compared to autologous frozen products equivalents in equine healthy joints. BMC Vet Res 2022;18(1):141.
  60. Gilbertie JM, Schaer TP, Engiles JB, Seiler GS, Deddens BL, Schubert AG. A platelet‐rich plasma‐derived biologic clears staphylococcus aureus biofilms while mitigating cartilage degeneration and joint inflammation in a clinically relevant large animal infectious arthritis model. Front Cell Infect Microbiol 2022;12:895022.
    doi: 10.3389/fcimb.2022.895022google scholar: lookup
  61. McLellan J, Plevin S. Does it matter which platelet‐rich plasma we use?. Equine Vet Educ 2011;23(2):101–104.
    doi: 10.1111/j.2042-3292.2010.00185.xgoogle scholar: lookup
  62. Van den Boom R, Van der Harst MR, Brommer H, Brama PA, Barneveld A, Van Weeren PR. Relationship between synovial fluid levels of glycosaminoglycans, hydroxyproline and general MMP activity and the presence and severity of articular cartilage change on the proximal articular surface of P1. Equine Vet J 2005;37(1):19–25.
    doi: 10.2746/0425164054406919google scholar: lookup
  63. McIlwraith CW, Frisbie DD, Kawcak CE. The horse as a model of naturally occurring osteoarthritis. Bone Joint Res 2012;1(11):297–309.
    doi: 10.1302/2046-3758.111.2000132google scholar: lookup
  64. Mishra A, Tummala P, King A, Lee B, Kraus M, Tse V. Buffered platelet‐rich plasma enhances mesenchymal stem cell proliferation and chondrogenic differentiation. Tissue Eng Part C Methods 2009;15(3):431–435.
    doi: 10.1089/ten.tec.2008.0534google scholar: lookup
  65. Sargeant JM, O'Connor AM, Gardner IA, Dickson JS, Torrence ME, Consensus Meeting Participants. The REFLECT statement: reporting guidelines for randomized controlled trials in livestock and food safety: explanation and elaboration. Zoonoses Public Health 2010;57(2):105–136.
    doi: 10.1111/j.1863-2378.2009.01312.xgoogle scholar: lookup
  66. Pietrzak WS, Eppley BL. Platelet rich plasma: biology and new technology. J Craniofac Surg 2005;16(6):1043–1054.
    doi: 10.1097/01.scs.0000186454.07097.bfgoogle scholar: lookup
  67. Smith J, Ross M, Smith R. Anabolic effects of acellular bone marrow, platelet rich plasma, and serum on equine suspensory ligament fibroblasts in vitro. Vet Comp Orthop Traumatol 2006;19:43–47.
    doi: 10.1055/s-0038-1632972google scholar: lookup
  68. Anitua E, Aguirre JJ, Algorta J, Ayerdi E, Cabezas AI, Orive G. Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers. J Biomed Mater Res – Part B Appl Biomater 2008;84(2):415–421.
    doi: 10.1002/jbm.b.30886google scholar: lookup
  69. Zimmermann R, Arnold D, Strasser E, Ringwald J, Schlegel A, Wiltfang J. Sample preparation technique and white cell content influence the detectable levels of growth factors in platelet concentrates. Vox Sang 2003;85(4):283–289.
    doi: 10.1111/j.0042-9007.2003.00361.xgoogle scholar: lookup
  70. Boff D, Crijns H, Teixeira MM, Amaral FA, Proost P. Neutrophils: beneficial and harmful cells in septic arthritis. Int J Mol Sci 2018;19(2):468.
    doi: 10.3390/ijms19020468google scholar: lookup
  71. Textor JA, Tablin F. Activation of equine platelet‐rich plasma: comparison of methods and characterization of equine autologous thrombin. Vet Surg 2012;41(7):784–794.
    doi: 10.1111/j.1532-950x.2012.01016.xgoogle scholar: lookup
  72. Fukuda K, Kuroda T, Tamura N, Mita H, Kasashima Y. Optimal activation methods for maximizing the concentrations of platelet‐derived growth factor‐BB and transforming growth factor‐β1 in equine platelet‐rich plasma. J Vet Med Sci 2020;82(10):1472–1479.
    doi: 10.1292/jvms.20-0167google scholar: lookup
  73. Lim A, Zhu JB, Khanduja V. The use of intra‐articular platelet‐rich plasma as a therapeutic intervention for hip osteoarthritis: a systematic review and meta‐analysis. Am J Sports Med 2023;51(9):2487–2497.
    doi: 10.1177/03635465221095563google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.